Wednesday, October 20, 2021
More

    Latest Posts

    Anti-inflammation drug combination may help pancreatic and liver cancer patients

    Pancreatic cancer cells (blue) that grow as spheres wrapped in a membrane (red). Credit: National Cancer Institute

    Discovered and developed decades ago in the laboratory of Bruce Hammock, a prominent professor at the University of California, Davis, a candidate drug has raging the body for chemotherapy treatment, especially for patients with pancreatic and liver cancer. , And often can help control the deadly inflammatory response.

    A research team based at Harvard Medical School and the Dipak Panigrahy Institute in Hammock Minutes of the National Academy of Sciences (((PNAS) this week.

    Working with a rodent model of the liver Pancreatic cancer, They found that they could be reduced using a combination of the two drugs inflammation After chemotherapy. Inflammation associated with debris from dying tumor cells metastasizes, cancer Whole body.

    “We have found that by inhibiting or blocking enzymes, the inflammation caused by chemotherapy can be reduced or eliminated. Soluble epoxide hydrolase (SEH), and EP4 prostaglandin receptors. “

    “Basically, blocking the eicosanoid pathways in both sEH and EP4 prevented the metastasis of pancreatic and liver cancer by working together to stimulate the removal of debris from previous cancer treatments,” Israel said. Panigrahee, a physician researcher at the Deacones Medical Center, said. , Harvard Medical College.

    The EP4 antagonist INV-1120 is currently in Phase I clinical trials in the United States, co-author Yongkui Sun, chairman of Chinese biotechnology company Ionova Life Science, discovers basic biomedical research. He said it would transform into a new treatment for cancer.

    Control upstream inflammation

    In a preclinical animal model, INV-1120 showed a synergistic effect with the sEH inhibitor anti-PD-1 in the fight against cancers such as pancreatic and liver cancer, according to Sun.

    The sEH and EP4 proteins play an important role in promoting inflammation. The hammock discovered the sEH pathway decades ago while studying butterfly metamorphosis. The sEH pathway has been found to be important in both human pain and inflammation. Hammock founded EicOsis Human Health LLC, based at the University of California, Davis, to bring sEH inhibitors to humans. Clinical trial, Currently in progress in Texas.

    “Controlling the body’s inflammatory response to chemotherapy is probably important to prevent metastases,” said the hammock. “I thought that what we really had to do was not to block cytokines, but to move upstream to regulate them and resolve them, but to block inflammation. . “

    The combination of drugs to block the sEH and EP4 pathways is a new approach to reducing inflammation and preventing cytokine storms caused by chemotherapy and tumor resection, the authors said.


    A new approach to avoiding inflammation caused by COVID-19


    For more information:
    Eicosanoid regulation of debris-stimulated metastasis, PNAS (2021). DOI: 10.1073 / pnas.2107771118

    Quote: The combination of anti-inflammatory drugs is https: //medicalxpress.com/news/2021-09-anti-inflammation-drug-combination-pancreatic-liver for pancreatic cancer and liver obtained on September 28, 2021. May be useful for patients with cancer (September 28, 2021). html

    This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

    Anti-inflammation drug combination may help pancreatic and liver cancer patients Source link Anti-inflammation drug combination may help pancreatic and liver cancer patients

    The post Anti-inflammation drug combination may help pancreatic and liver cancer patients appeared first on California News Times.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.